JP2020517640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517640A5 JP2020517640A5 JP2019556889A JP2019556889A JP2020517640A5 JP 2020517640 A5 JP2020517640 A5 JP 2020517640A5 JP 2019556889 A JP2019556889 A JP 2019556889A JP 2019556889 A JP2019556889 A JP 2019556889A JP 2020517640 A5 JP2020517640 A5 JP 2020517640A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- adc
- cancer
- individual
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C1)CC=C(C2)[C@]1C(C)C(*)c(c(*)c(CC*c(c(*)c1N(*)C(C3N4C=C(*)C3)*=*)c(*)c(*)c1C4=O)c(*)c1*)c1C2=O Chemical compound CC(C1)CC=C(C2)[C@]1C(C)C(*)c(c(*)c(CC*c(c(*)c1N(*)C(C3N4C=C(*)C3)*=*)c(*)c(*)c1C4=O)c(*)c1*)c1C2=O 0.000 description 1
- SDUQYLNIPVEERB-ZJXFTUPMSA-N NC(C=CN1[C@@H](C2(F)F)O[C@H](CO)C2O)=NC1=O Chemical compound NC(C=CN1[C@@H](C2(F)F)O[C@H](CO)C2O)=NC1=O SDUQYLNIPVEERB-ZJXFTUPMSA-N 0.000 description 1
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706259.7A GB201706259D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GBGB1706257.1A GB201706257D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GBGB1706253.0A GB201706253D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GB1706253.0 | 2017-04-20 | ||
| GB1706257.1 | 2017-04-20 | ||
| GB1706260.5 | 2017-04-20 | ||
| GB1706259.7 | 2017-04-20 | ||
| GBGB1706260.5A GB201706260D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GB1706258.9 | 2017-04-20 | ||
| GB1706254.8 | 2017-04-20 | ||
| GBGB1706258.9A GB201706258D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GB1706261.3 | 2017-04-20 | ||
| GB1706256.3 | 2017-04-20 | ||
| GBGB1706261.3A GB201706261D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GBGB1706254.8A GB201706254D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GBGB1706256.3A GB201706256D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GB1802947.0 | 2018-02-23 | ||
| GBGB1802947.0A GB201802947D0 (en) | 2018-02-23 | 2018-02-23 | Combination therapy |
| GBGB1805660.6A GB201805660D0 (en) | 2018-04-05 | 2018-04-05 | Combination Therapy |
| GB1805660.6 | 2018-04-05 | ||
| PCT/EP2018/060215 WO2018193105A1 (en) | 2017-04-20 | 2018-04-20 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517640A JP2020517640A (ja) | 2020-06-18 |
| JP2020517640A5 true JP2020517640A5 (https=) | 2021-08-12 |
Family
ID=62111031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556889A Pending JP2020517640A (ja) | 2017-04-20 | 2018-04-20 | 併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200405879A1 (https=) |
| EP (1) | EP3612839A1 (https=) |
| JP (1) | JP2020517640A (https=) |
| KR (1) | KR20190137151A (https=) |
| CN (1) | CN110869765A (https=) |
| AU (1) | AU2018253951A1 (https=) |
| BR (1) | BR112019021822A2 (https=) |
| CA (1) | CA3057749A1 (https=) |
| MX (1) | MX2019012462A (https=) |
| WO (1) | WO2018193105A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2902686C (en) | 2013-04-25 | 2017-01-24 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| WO2018033853A2 (en) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| WO2018033135A1 (en) * | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
| US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| MX2020010523A (es) | 2017-02-27 | 2021-02-09 | Third Pole Inc | Sistemas y metodos para generar oxido nitrico. |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| ES3037206T3 (en) * | 2018-08-31 | 2025-09-30 | Adc Therapeutics Sa | Combination therapy |
| WO2020109251A1 (en) * | 2018-11-29 | 2020-06-04 | Adc Therapeutics Sa | Dosage regime |
| JP7574198B2 (ja) * | 2019-01-18 | 2024-10-28 | ドラセン ファーマシューティカルズ インコーポレイテッド | Ｄｏｎプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法 |
| WO2020232414A1 (en) | 2019-05-15 | 2020-11-19 | Third Pole, Inc. | Architectures for production of nitric oxide |
| CN110128551A (zh) * | 2019-06-05 | 2019-08-16 | 上海科弈药业科技有限公司 | 一种针对cd19+肿瘤的多功能融合蛋白及其应用 |
| GB201908128D0 (en) * | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| AU2020292965A1 (en) * | 2019-06-10 | 2022-01-27 | Adc Therapeutics Sa | Combination therapy comprising an anti-CD19 antibody drug conjugate and a PI3K inhibitor or a secondary agent |
| US20220249491A1 (en) | 2019-06-10 | 2022-08-11 | Beigene Switzerland Gmbh | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor |
| KR20220054853A (ko) | 2019-09-03 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치료 방법 |
| EP4069069A4 (en) | 2020-01-11 | 2024-07-03 | Third Pole, Inc. | SYSTEMS AND METHODS FOR NITROGEN OXIDE PRODUCTION WITH HUMIDITY CONTROL |
| EP4167920A4 (en) | 2020-06-18 | 2024-06-12 | Third Pole, Inc. | Systems and methods for preventing and treating infections with nitric oxide |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| WO2022082072A1 (en) | 2020-10-16 | 2022-04-21 | Third Pole, Inc. | Nitric oxide generation process controls |
| TW202244059A (zh) * | 2021-04-30 | 2022-11-16 | 瑞士商赫孚孟拉羅股份公司 | 用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥 |
| EP4362983A1 (en) | 2021-06-29 | 2024-05-08 | ADC Therapeutics SA | Combination therapy using antibody-drug conjugates |
| EP4405019A4 (en) | 2021-09-23 | 2025-07-16 | Third Pole Inc | SYSTEMS AND METHODS FOR PROVIDING NITRIC OXIDE |
| WO2023201363A2 (en) | 2022-04-14 | 2023-10-19 | Third Pole, Inc. | Delivery of medicinal gas in a liquid medium |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| EP4410314A1 (en) * | 2023-02-02 | 2024-08-07 | ADC Therapeutics SA | Combination therapy comprising anti-cd22 antibody-drug conjugate and irak1 inhibitor |
| WO2025249980A1 (ko) * | 2024-05-31 | 2025-12-04 | (주)노보메디슨 | 림프종의 예방 또는 치료를 위한 포셀티닙의 병용투여 요법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP2550975A1 (en) * | 2011-07-29 | 2013-01-30 | Sanofi | Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab |
| HRP20182129T1 (hr) * | 2012-10-12 | 2019-02-08 | Adc Therapeutics Sa | Konjugati protutijelo - pirolobenzodiazepin |
| MX338711B (es) * | 2012-10-12 | 2016-04-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| BR112015027474A8 (pt) * | 2013-05-02 | 2018-01-23 | Hoffmann La Roche | anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo. |
| WO2015052534A1 (en) * | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| GB201506399D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
-
2018
- 2018-04-20 EP EP18721976.1A patent/EP3612839A1/en not_active Withdrawn
- 2018-04-20 AU AU2018253951A patent/AU2018253951A1/en not_active Abandoned
- 2018-04-20 KR KR1020197033821A patent/KR20190137151A/ko not_active Ceased
- 2018-04-20 US US16/605,701 patent/US20200405879A1/en not_active Abandoned
- 2018-04-20 CA CA3057749A patent/CA3057749A1/en active Pending
- 2018-04-20 MX MX2019012462A patent/MX2019012462A/es unknown
- 2018-04-20 CN CN201880038974.5A patent/CN110869765A/zh active Pending
- 2018-04-20 JP JP2019556889A patent/JP2020517640A/ja active Pending
- 2018-04-20 BR BR112019021822-0A patent/BR112019021822A2/pt not_active IP Right Cessation
- 2018-04-20 WO PCT/EP2018/060215 patent/WO2018193105A1/en not_active Ceased
-
2022
- 2022-08-11 US US17/819,185 patent/US20230149556A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230149556A1 (en) | Combination therapy | |
| JP2020517640A5 (https=) | ||
| JP6591428B2 (ja) | 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ | |
| JP7402691B2 (ja) | 抗ｃｄ２５抗体薬物複合体による併用療法 | |
| JP2020517629A5 (https=) | ||
| EP3303399A1 (en) | Methods of treating cancer using anti-ox40 antibodies | |
| WO2016200835A1 (en) | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists | |
| JP2020517652A5 (https=) | ||
| US20200129638A1 (en) | Combination therapy with an anti-psma antibody-drug conjugate | |
| KR20210006405A (ko) | 암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제 | |
| KR20190135028A (ko) | 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용 | |
| JP7740994B2 (ja) | 抗ｃｄ１９抗体薬物複合体とｐｉ３ｋ阻害剤又は二次薬剤を含む併用治療 | |
| JP7590083B2 (ja) | 併用療法 | |
| KR20250052418A (ko) | 항-ccr8 항체 및 그의 용도 | |
| KR20220095205A (ko) | 암의 치료를 위한 방사선요법과 PD-1, TGFβ 및 ATM의 조합 억제 | |
| JP2021533090A (ja) | 併用療法 | |
| EA046551B1 (ru) | Комбинированная терапия |